Basis: FMP quote market capitalization / revenue from four consecutive issuer fiscal quarters. Source: stored company filings and market data; unavailable inputs remain N/A.
The P/S ratio is N/A as of 2026-10-06T16:10:28.509Z.
Calculation as of: 2026-10-06T16:10:28.509Z.
Quote observation: 2026-10-06T16:10:15.000Z. Amounts in USD. The price header may show a later quote.
FMP input reference: a29a88061d86e64317c53e71c63756e58f7ffa0b55551e6148327154cc786467
Historical values estimate market capitalization from statement-period weighted shares. Comparisons with the current quote-based value are approximate. Only filing versions delivered by FMP are available for the historical calculation.
PS RATIO
N/A
Market Cap
$20.54M
PS Ratio
N/A
TTM Avg
252.77
3Y Avg
5169.56
5Y Avg
5169.56
Market Cap
$18.54M
PS Ratio
15.79
TTM Avg
3.71
3Y Avg
52.88
5Y Avg
45311.56
| NAME | MARKET CAP | PS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Actuate Therapeutics Inc (ACTU) | $19.98M | N/A | N/A | N/A | N/A |
| P3 Health Partners Inc. (PIII)vs › | $19.66M | 0.01 | 0.02 | 0.04 | 0.14 |
| Quantum BioPharma Ltd. (QNTM)vs › | $20.54M | N/A | 252.77 | 5169.56 | 5169.56 |
| Modular Medical, Inc. (MODD)vs › | $20.38M | N/A | N/A | N/A | N/A |
| NextCure, Inc. (NXTC)vs › | $19.25M | N/A | 15.99 | 112.90 | 112.90 |
| Neuphoria Therapeutics Inc. (NEUP)vs › | $18.54M | 15.79 | 3.71 | 52.88 | 45311.56 |
| Estrella Immunopharma, Inc. (ESLA)vs › | $18.40M | N/A | N/A | N/A | N/A |
| LeonaBio, Inc. (LONA)vs › | $22.44M | N/A | N/A | N/A | N/A |
| Aytu BioPharma, Inc. (AYTU)vs › | $22.65M | 0.39 | 0.46 | 0.28 | 0.24 |
| Rein Therapeutics Inc. (RNTX)vs › | $22.75M | N/A | N/A | N/A | N/A |
Trailing-12-month revenue adds these four fiscal quarters. Amounts are in USD, rounded only to whole currency units.
| Fiscal period | Revenue | Source |
|---|---|---|
| Q3 FY2025Period ended 2025-09-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2025-11-13 |
| Q4 FY2025Period ended 2025-12-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-03-26 |
| Q1 FY2026Period ended 2026-03-31 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-05-14 |
| Q2 FY2026Period ended 2026-06-30 | $0 | Filing link unavailableFMP normalized income statementFiling date supplied by FMP: 2026-08-14 |
| TTM revenue | $0 |
The current P/S calculation cannot be reconciled from the stored quote and revenue inputs.
These references are supplied through FMP. Full filing context identifiers and dimensional metadata are unavailable in the normalized feed.
P/S Ratio
N/A
Market Cap / Trailing Twelve-Month Revenue
PS Ratio = Market Cap / Revenue (TTM)
The price-to-sales ratio compares market capitalization to trailing revenue. It is useful for valuing companies with little or no earnings.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
